ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

Abstract excerpt

Most melanoma patients with BRAF V600E positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the treatment. For patients insufficiently responding to BRAF and MEK inhibitors, there is an ongoing need for new treatment targets. Cellular metabolism is such a promising...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytokine Signaling Pathways and Interactions
• Share to melanin and skin pigmentation
• Share to Melanoma and MAPK Pathways